What is the survival rate of Kymriah?

Kymriah (tisagenlecleucel) is a CAR T-cell therapy used to treat certain types of relapsed or refractory (r/r) blood cancers. Ongoing clinical studies continue to assess its long-term survival rates.

Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell acute lymphoblastic leukemia is 55%.

Survival Rates by Cancer Type

Children and young adults with advanced B-cell acute lymphoblastic leukemia (ALL)

The five-year overall survival rate in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) is 55%. This means that 55% of patients treated with Kymriah were still alive after 5 years. This data is from the ELIANA clinical trial that included 79 patients.

Adults with relapsed or refractory diffuse large B-cell lymphoma

According to the Center for International Blood and Marrow Transplant Research CIBMTR, the 24-month overall survival rate was 43.6% out of 1159 patients receiving Kymriah for aggressive B-cell non-Hodgkin’s lymphoma. Another study reported a 12-month survival rate of 59%.

Adults with relapsed or refractory follicular lymphoma

In the ELARA study, the estimated 24-month progression-free survival was 57.4%. The overall survival was 87.7%. The ELARA study included 97 patients.

These findings highlight Kymriah’s potential benefits in various blood cancers, though research is ongoing to confirm long-term efficacy.